"We are very pleased to form this partnership with InVivo Therapeutics and look forward to evaluating its innovative biopolymer scaffolding device," said Marc Buoniconti, President of the Miami Project "We have been working on the problem of SCI for more than 25 years and look forward to exploring another promising avenue in our quest to address the enduring need for effective treatment options. The InVivo team shares our passion and personal commitment to finding new solutions to the challenges of spinal cord injury and paralysis."
Schwann cells are an integral component of The Miami Project's research strategy because they are an important component of the peripheral nervous system. The cells are known to insulate (myelinate) and promote the growth and regeneration of nerve fibers. In preclinical models, Miami Project scientists have demonstrated locomotor function recovery, spared nerve function and nerve cell growth using autologous Schwann cell transplantation. The Miami Project has completed preclinical studies and plans to file an Investigational New Drug (IND) application for a Phase 1 human study using Schwann cells with the U.S. Food and Drug Administration in 2011.
"InVivo's biopolymer scaffoldings are novel tissue engineering solutions that may serve to improve functional recovery and promote the proliferation and survival of cellular therapies such as Schwann cells at the site of injury," said W. Dalton Dietrich, III, Ph.D., Scientific Director of The Miami Project. "We see significant potential in the natural synergies from combining these treatment approaches, both of which have been validated in preclinical studies. The Miami Project team looks forward to elucidating their potential and to worki
|SOURCE The Miami Project; InVivo Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved